Definitive Healthcare Corp. (DH) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Next, we'll hear from Jeff Guerra of Stevens Inc. Yeah, good afternoon. Thanks for taking the question. I want to go further on the life science and market. The two highlighted wins in the release are both life science or biopharma related. And you also gave several more examples on the call. So I think clearly you have some proof points of value with those kind of large and sophisticated customers. And it all kind of contrasts with the broader decline you've described for that segment. So I was hoping you could elaborate on the life science segment, the kind of overall demand environment, the recent win rate that DFIN has had within that segment. And lastly, just when the claims disruption will stop being a factor for that segment. Thanks. Perfect. So I will start with the last first, which if you think about the likely cohort cycle that we'll be in. So, having returned to historical levels of claims data, and in fact, now in the first quarter, we're now above historical levels, and often those customers were buying data based on records and size of data payload, So when you have potentially, let's say, a 30% decline in records, that was what was the factor pushing on our downsell pressure, which we've largely worked through. Now that we've returned to those historical levels, we expect that the customers that we are now entitling today will actually not experience the same level of down pressure when they come up for their renewals. We started to see that shift as we were repairing the claims data set later last year. But, you know, unfortunately, a lot of buying decisions are made earlier than we were able to get that in market. And so, we think we're seeing the tail of it now, right? It's not a perfect science, but we believe that we've sort of experienced the wo...